"...biotechs, depending on the stage of product development, have irregular periods of cash flow. So, periods of lower growth in the upcoming years is not out of the ordinary..."
What!? Man, did Humanigen pay for that ad?
I think I read that we reported $311K in revenue last year. And the analysts are estimating $500M - $1B in '21?
And stockpiling demand, both in the US and internationally.
I think it's a little misleading to suggest an expectation of "lower growth in the coming years." It will take the remaining 9 months of this year, and all of FY22 to penetrate the Covid (-type) market on a world-wide basis. By that time, we'll be well into commercialization of lenz for what should be a booming CAR-T therapy market. The first patient has already been dosed in the Zuma trial. And the ifab trial has already completed clinical trial enrollment for the treatment of solid tumors.
I see year-over-year aggressive growth, with an absolutely jaw-dropping explosion of growth in the immediate time frame. I don't think we need to worry about a "7.5%" growth rate for some very happy time from now.
MARCH GLADNESS!
News 
Market Data 
Discover 
